Core Insights - The total addressable market for GLP-1 pills is significant, with over 100 million Americans affected by obesity, indicating a large potential user base for these medications [2][3] - The transition from injectable to oral forms of GLP-1 drugs is expected to increase accessibility and adoption among patients who dislike injections, potentially leading to a higher uptake of these treatments [2][3] Market Dynamics - Novo Nordisk is currently leading the market with its GLP-1 drug, while Eli Lilly is expected to follow closely behind, likely launching its product a few months later [3][4] - The competitive landscape is characterized by a rush to enroll patients before Eli Lilly's product becomes available, as established users may be reluctant to switch medications once they start seeing results [4] Efficacy and Health Impact - Both Novo Nordisk and Eli Lilly's drugs are anticipated to be effective in promoting weight loss and improving related health conditions, with Eli Lilly's product potentially offering slightly better results [5] - A significant increase in the number of users, particularly among those who avoid injections, could lead to improved health outcomes and potentially lower healthcare costs in the long term, despite initial higher expenses associated with these drugs [5][7] Long-term Outlook - The initial phase may see increased healthcare costs due to the high price of these medications, but the long-term health benefits could lead to improved longevity and overall health for the population [6][7] - The focus of these drugs is primarily on health improvement rather than cost reduction, emphasizing the importance of enhancing quality of life and longevity for users [8]

Welcome back to Fast Money. Structure Therapeutic shares doubling today. The stock's best day on record.The biotech out with new data on its once daily GLP1 pill showing patients lost an average 11.3% of their body weight after 36 weeks of treatment. For more, let's bring in Missouo healthcare strategist Jared Holes. Jared, great to have you with us.Um, should Lily be concerned. Should investors in Lily be concerned about this. >> Hey Melissa, I really appreciate it.Um, maybe a little bit. I mean, structure ...